Trials / Unknown
UnknownNCT02404675
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Betta Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This randomized, open-label study is aimed to evaluate the efficacy of high-dose icotinib in treating advanced non-small cell lung cancer patients with positive EGFR 21 exon mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | icotinib |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2017-12-01
- Completion
- 2018-09-01
- First posted
- 2015-03-31
- Last updated
- 2017-07-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02404675. Inclusion in this directory is not an endorsement.